Ladrx CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
LADX
Ladrx CORP10-K: LadRx Corporation Reports Annual Results for 2024, Outlines Strategy for Aldoxorubicin Approval
LadRx Corporation announces its 2024 annual results, highlighting a net loss but outlining plans to pursue FDA approval for aldoxorubicin and advance its LADR-7 drug candidate.
OTC.Pink
LADX
Ladrx CORPLadRx Corporation's 2023 annual report highlights a shift towards advancing its LADR7 drug candidate after a strategic royalty agreement, despite ongoing operational losses.